Posted on

A modern twist on a decades-old therapy technique

Incannex Executes License Agreement with Monash University to Develop a Combination Treatment Using Virtual Reality and Psychedelics

Exposure therapy has been a common treatment for anxiety disorders (especially OCD) since the 70’s. It involves gradually exposing patients to triggering situations in a safe environment so they can work through their irrational response.

Now imagine being exposed to your triggers through immersive virtual reality… while on psychedelics.

It may sound scary, but psychedelics could actually provide feelings of safety and allow patients to change their perspective and response to the stimuli.

This is how Incannex Healthcare (IXL) plans to treat patients with severe anxiety disorders in upcoming trials in collaboration with Monash University.

The Australian company debuted on the Nasdaq this week under the symbol ‘IXHL’.

662

PDF of article 1

PDF of article 2

Posted on

24 hour trip anyone?

MINDCURE Achieves Key Development Milestone for Novel Ibogaine Program

Tripping on ibogaine can last over 24 hours, and it’s not always pleasant. But the wide range of benefits could make it worthwhile. 

MINDCURE (MCUR) hopes so at least. The company filed a provisional patent for synthetic ibogaine mixtures to treat various central nervous system disorders like:

  • Addiction
  • Traumatic brain injury
  • Anxiety disorders
  • Chronic pain such as migraines and cluster headaches

The company aims to be a global supplier of synthetic ibogaine for research purposes and expects to have supply available by the end of Q2 this year.

PDF of article

‍

Posted on

LSD and psilocybin have the same effects, apparently

MindMed Announces Publication of Study Comparing the Acute Effects of Lysergic Acid Diethylamide and Psilocybin in Healthy Subjects

MindMed’s latest study compared the experiences of LSD and psilocybin in high and low doses. 

Subjects were assessed on a scale that measures changes in consciousness like feelings of unity and bliss, ego dissolution, auditory and visual sensations, spiritual experiences, and insightfulness.

Researchers found “no evidence of qualitative differences in altered states of consciousness”  between the substances, except that LSD lasted longer. Any other differences could be attributed to the dose, not the substance.

They found that 20 mg psilocybin is equivalent to 100 µg LSD (a 1:200 ratio), and that body weight had no influence on the concentration of the drugs in blood plasma.

Posted on

Braxia Scientific Reports Q3 2022 Financial Results; Company Leads in Psychedelic Research, Access and Therapist Training with First Multi-Dose Psilocybin Trial in Canada

Braxia Scientific Reports Q3 2022 Financial Results; Company Leads in Psychedelic Research, Access and Therapist Training with First Multi-Dose Psilocybin Trial in Canada

Braxia Scientific (BRAX) reported quarterly financial results including $324K in revenue (up 13.3% year-over-year), $7.64M in cash, and a $2.52M net loss. 

Braxia Scientific Corp.

PDF of article

Posted on

Are psychedelics the key to a healthy family dynamic?

‘I Did Ayahuasca With My Parents And It Deepened Our Relationship’

To learn more about psychedelic medicine, Dr. Adele Lafrance attended an ayahuasca ceremony with her parents. It was so transformative that she’s planning to conduct studies on how psychedelics can support healthy family relationships.

She explains that the ceremony “planted the seeds for deeper emotional intimacy” and allowed her family to talk about love in a vulnerable way for the first time. The experience helped her heal from painful childhood memories.

“I felt a level of understanding toward my parents that was so deep, forgiveness wasn’t necessary. It was beautiful.”

PDF of article